2 recruiting, 1 suspended. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Suspended 1 |
Follow NextPoint Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies NPX372 - Metastatic Malignant Neoplasm | Phase 1 | Recruiting | NextPoint Therapeutics, Inc. | 81 | 2026-05-01 | 2026-09-08 |
| A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2 NPX887 - Metastatic Malignant Neoplasm | Phase 1 | Recruiting | NextPoint Therapeutics, Inc. | 144 | 2024-01-22 | 2025-06-27 |
| A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 NPX267 - Metastatic Malignant Neoplasm | Phase 1 | Suspended | NextPoint Therapeutics, Inc. | 131 | 2023-07-21 | 2025-06-27 |
Neoplasm Metastasis (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Osteosarcoma (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
United States (3) · South Korea (1)
Leena Gandhi, MD, PhD (2) · Leena Gandhi, MD, Ph.D. (1)